Now showing items 1-3 of 3

    • Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. 

      Peterlongo, P; Chang-Claude, J; Moysich, KB; Rudolph, A; Schmutzler, RK; Simard, J; Soucy, P; Eeles, RA; Easton, DF; Hamann, U; Wilkening, S; Chen, B; Rookus, MA; Schmidt, MK; van der Baan, FH; Spurdle, AB; Walker, LC; Lose, F; Maia, A-T; Montagna, M; Matricardi, L; Lubinski, J; Jakubowska, A; Gómez Garcia, EB; Olopade, OI; Nussbaum, RL; Nathanson, KL; Domchek, SM; Rebbeck, TR; Arun, BK; Karlan, BY; Orsulic, S; Lester, J; Chung, WK; Miron, A; Southey, MC; Goldgar, DE; Buys, SS; Janavicius, R; Dorfling, CM; van Rensburg, EJ; Ding, YC; Neuhausen, SL; Hansen, TVO; Gerdes, A-M; Ejlertsen, B; Jønson, L; Osorio, A; Martínez-Bouzas, C; Benitez, J; Conway, EE; Blazer, KR; Weitzel, JN; Manoukian, S; Peissel, B; Zaffaroni, D; Scuvera, G; Barile, M; Ficarazzi, F; Mariette, F; Fortuzzi, S; Viel, A; Giannini, G; Papi, L; Martayan, A; Tibiletti, MG; Radice, P; Vratimos, A; Fostira, F; Garber, JE; Donaldson, A; Brewer, C; Foo, C; Evans, DGR; Frost, D; Eccles, D; Brady, A; Cook, J; Tischkowitz, M; Adlard, J; Barwell, J; Walker, L; Izatt, L; Side, LE; Kennedy, MJ; Rogers, MT; Porteous, ME; Morrison, PJ; Platte, R; Davidson, R; Hodgson, SV; Ellis, S; Cole, T; EMBRACE; Godwin, AK; Claes, K; Van Maerken, T; Meindl, A; Gehrig, A; Sutter, C; Engel, C; Niederacher, D; Steinemann, D; Plendl, H; Kast, K; Rhiem, K; Ditsch, N; Arnold, N; Varon-Mateeva, R; Wappenschmidt, B; Wang-Gohrke, S; Bressac-de Paillerets, B; Buecher, B; Delnatte, C; Houdayer, C; Stoppa-Lyonnet, D; Damiola, F; Coupier, I; Barjhoux, L; Venat-Bouvet, L; Golmard, L; Boutry-Kryza, N; Sinilnikova, OM; Caron, O; Pujol, P; Mazoyer, S; Belotti, M; GEMO Study Collaborators; Piedmonte, M; Friedlander, ML; Rodriguez, GC; Copeland, LJ; de la Hoya, M; de la Hoya, M; Segura, PP; Nevanlinna, H; Aittomäki, K; van Os, TAM; Meijers-Heijboer, HEJ; van der Hout, AH; Vreeswijk, MPG; Hoogerbrugge, N; Ausems, MGEM; van Doorn, HC; Collée, JM; HEBON; Olah, E; Diez, O; Blanco, I; Lazaro, C; Brunet, J; Feliubadalo, L; Cybulski, C; Gronwald, J; Durda, K; Jaworska-Bieniek, K; Sukiennicki, G; Arason, A; Chiquette, J; Teixeira, MR; Olswold, C; Couch, FJ; Lindor, NM; Wang, X; Szabo, CI; Offit, K; Corines, M; Jacobs, L; Robson, ME; Zhang, L; Joseph, V; Joseph, V; Berger, A; Singer, CF; Rappaport, C; Kaulich, DG; Pfeiler, G; Tea, M-KM; Phelan, CM; Greene, MH; Mai, PL; Rennert, G; Mulligan, AM; Glendon, G; Tchatchou, S; Andrulis, IL; Toland, AE; Bojesen, A; Pedersen, IS; Thomassen, M; Jensen, UB; Laitman, Y; Rantala, J; von Wachenfeldt, A; Ehrencrona, H; Askmalm, MS; Borg, Å; Kuchenbaecker, KB; McGuffog, L; Barrowdale, D; Healey, S; Lee, A; Pharoah, PDP; Chenevix-Trench, G; KConFab Investigators; Antoniou, AC; Friedman, E (2015-01)
      Background BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation ...
    • Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. 

      Mavaddat, N; Antoniou, AC; Mooij, TM; Hooning, MJ; Heemskerk-Gerritsen, BA; GENEPSO; Noguès, C; Gauthier-Villars, M; Caron, O; Gesta, P; Pujol, P; Lortholary, A; EMBRACE; Barrowdale, D; Frost, D; Evans, DG; Izatt, L; Adlard, J; Eeles, R; Brewer, C; Tischkowitz, M; Henderson, A; Cook, J; Eccles, D; HEBON; van Engelen, K; Mourits, MJE; Ausems, MGEM; Koppert, LB; Hopper, JL; John, EM; Chung, WK; Andrulis, IL; Daly, MB; Buys, SS; kConFab Investigators; Benitez, J; Caldes, T; Jakubowska, A; Simard, J; Singer, CF; Tan, Y; Olah, E; Navratilova, M; Foretova, L; Gerdes, A-M; Roos-Blom, M-J; Van Leeuwen, FE; Arver, B; Olsson, H; Schmutzler, RK; Engel, C; Kast, K; Phillips, K-A; Terry, MB; Milne, RL; Goldgar, DE; Rookus, MA; Andrieu, N; Easton, DF; IBCCS; kConFab; BCFR (2020-01-16)
      BACKGROUND:The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially ...
    • Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. 

      Girardi, F; Barnes, DR; Barrowdale, D; Frost, D; Brady, AF; Miller, C; Henderson, A; Donaldson, A; Murray, A; Brewer, C; Pottinger, C; Evans, DG; Eccles, D; EMBRACE; Lalloo, F; Gregory, H; Cook, J; Eason, J; Adlard, J; Barwell, J; Ong, KR; Walker, L; Izatt, L; Side, LE; Kennedy, MJ; Tischkowitz, M; Rogers, MT; Porteous, ME; Morrison, PJ; Eeles, R; Davidson, R; Snape, K; Easton, DF; Antoniou, AC (2018-12)
      Purpose BRCA1/BRCA2 predictive test negatives are proven noncarriers of a BRCA1/BRCA2 mutation that is carried by their relatives. The risk of developing breast cancer (BC) or epithelial ovarian cancer (EOC) in these women ...